A Randomized, Double-blind, Placebo Controlled Trial (RCT) of Varenicline to Reduce Alcohol Consumption in Heavy Drinkers
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Alcohol Consumption
研究概览
简要总结
This study will determine whether varenicline, a drug that acts on the brain's nicotine receptors and is used to help smokers stop smoking, will have an impact on alcohol self-administration.
People between 24 and 60 years of age who regularly consume alcoholic drinks (more than 15 drinks per week for women, and more than 20 drinks per week for men) may be eligible for this study. The study requires five outpatient visits and one overnight hospital admission at the NIH Clinical Center.
Participants undergo the following procedures:
Visit 1 (outpatient: 4-5 hours)
- Standard assessments, including vital signs measurements, breathalyzer test, blood and urine tests (including pregnancy test for females), questionnaires about mood, symptoms, alcohol use and smoking, if applicable
- Questionnaires about medical and psychological status
- Health assessment and assessment of alcohol drinking behavior
Visit 2 (outpatient: 8 hours)
- Standard assessments (see above)
- Computer-Assisted Self-infusion of Ethanol (CASE) session: Subjects will receive a priming intravenous infusion of alcohol. After 25 min, they will be allowed to give themselves additional exposures of alcohol over a period of 2 hours by pressing a button on a computer that controls the infusion pump.
Visit 3 (outpatient: 2 hours)
-Standard assessments
Visit 4 (outpatient: 8 hours)
- Standard assessments
- Brain functional magnetic resonance imaging scan (MRI). This test uses a magnetic field and radio waves to produce images of the brain. The patient lies on a table that can slide in and out of the scanner, wearing earplugs to muffle loud sounds that occur during the scanning process. Initial pictures are taken of the brain's structure and additional scans measure brain activity while the subject performs simple tasks.
- Alcohol Infusion. Subjects receive an intravenous infusion of alcohol while in the MRI scanner to measure the brain s response to alcohol.
Visit 5 (overnight)
- Standard assessments
- Repeat CASE session
- Interview about the subject's experiences participating in the protocol, including any symptoms and urges to drink
Visit 6 (outpatient)
- Standard assessments (without blood tests)
- Interview about participation in the study
Telephone follow-up
After 3 weeks, subjects are called to check on their symptoms and gather information on their drinking and, if applicable, smoking.
详细描述
Objective:
Considerable clinical and experimental evidence in humans and animal models links nicotine use with heavy alcohol consumption. Varenicline, an alpha4beta2 (nicotinic) acetylcholine receptor (nAchR) partial agonist, is an oral medication approved by the FDA (2006) for smoking cessation. Recently, it has been shown to reduce alcohol consumption in a rodent model of alcohol dependence. In the present short-term experimental study, it will be assessed primarily for its ability to reduce alcohol self-administration in heavy drinkers. Secondarily, its effects on alcohol urges (cravings), as well as smoking parameters will be measured. In addition, effects of varenicline on incentive motivation for alcohol and the underlying brain reward system activation, as well as on activation of brain reward systems in response to intravenously administered alcohol will be measured.
Study Population:
Fifty healthy, adults (smokers and non-smokers), age 21 to 60 years, will be studied. Individuals must drink alcohol regularly at a heavy level, on average greater than 20 drinks per week for men, and greater than 15 drinks per week for women, and not be seeking help for alcohol-related problems.
Design:
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 21 Years 至 60 Years(Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
Varenicline
Varenicline tablets, 2 mg per day for 3 weeks
干预措施: Varenicline (Drug)
Placebo
Placebo tablets, 0 mg per day for 3 weeks
干预措施: Placebo (Drug)
结局指标
主要结局
Alcohol Consumption
时间窗: 2.5 hr session following 3 weeks of treatment
Peak Breath Alcohol Concentration during IV alcohol self-administration
次要结局
- Alcohol Urges(2.5 hr session following 3 weeks of treatment)
研究者
Vijay Ramchandani, Ph.D.
Clinical Investigator and Chief, Section on Human Psychopharmacology
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
